Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. The decision to change the title of the journal has been taken after a great year for touchONCOLOGY, and we feel that in an increasingly global research community, submissions were being limited by an assumed primary reach to one regional audience. Together with the recent closure of European Oncology & Haematology, this will allow the journal to grow, while reflecting the new international audience in the change of title.
We are excited to bring you a range of interesting and informative articles in this issue. touchREVIEWS in Oncology & Haematology would like to thank our contributors for producing insightful and informative articles. We are also grateful to all organizations and society partners for their ongoing support, and the members of our editorial board for their continued involvement and advice. We hope that you will find this edition enjoyable and thought-provoking. If you are interested in being published in future editions, you can submit a manuscript here.
Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 1 – 2021
Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. As co-editors-in-chief of this new title, we are excited to bring you a range of interesting and informative […]
Criteria for Evaluating Multi-cancer Early Detection Tests
Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1 However, early attempts with targeted sequencing of circulating tumour cfDNA to screen for multiple cancers were unsuccessful because of low sensitivity […]
COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect?
Advanced age and other comorbid conditions put patients with chronic lymphocytic leukaemia (CLL) at an increased risk of morbidity and mortality from SARS-CoV-2 infection, with early studies showing case fatality rates of over 30% in patients with CLL with symptomatic COVID-19.1,2 As the vaccination against COVID-19 is becoming available for use in the general population, its […]
Implementing the European Code of Cancer Practice to Improve Europe’s Cancer Outcomes
The European Code of Cancer Practice The European Code of Cancer Practice is a patient-centred manifesto of the key features required to deliver good clinical cancer practice and improve patient outcomes in Europe.1,2 It builds upon the European Cancer Patient’s Bill of Rights, which was launched in the European Parliament on World Cancer Day 2014 and […]
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer
The metastatic setting has traditionally been the initial venue for the development of new drugs in breast cancer. This seems like a natural population in which to start because patients have often exhausted the armamentarium of approved agents and, therefore, clinical equipoise is easier to achieve. These trials, however, often involve sicker patients who can […]
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract, accounting for 0.1–3.0% of all GI malignancies, and 80% of all GI sarcomas.1–5 While GISTs can occur throughout the entire GI tract, with similar male/female incidence, 60% of cases usually present in the stomach, and about 30% in the small […]
High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy
Endometrial cancer has become an increasingly significant cause of morbidity and mortality for women. Currently, endometrial cancer is the most common invasive gynaecologic malignancy, and the ninth most common cancer among women in the USA, accounting for approximately 65,620 new cancer cases and 12,590 deaths in 2020.1 The 5-year relative survival rate is estimated to be […]
New Approaches to Allogeneic Haematopoietic Cell Transplantation
Allogeneic haematopoietic cell transplantation (allo-HCT) has a bi-faceted role in the treatment of haematopoietic malignancies. First, allo-HCT gives high-dose chemotherapy a chance to reduce the leukaemic burden; second, it allows graft-originated natural killer and T cells to initiate an adoptive immunotherapy effect against leukaemic cells via tumour-specific antigens, tumour-associated antigens and minor histocompatibility antigens.1–6 Allo-HCT plays […]
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the treatment of patients without oncogenic drivers. Consequently, the lives of patients with NSCLC have significantly […]
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in tumour cells. Patients often relapse even after autologous stem cell transplant and multiple lines […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!